Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Ocular Pharmacology and Therapeutics in a compact format. The editors have built Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Ocular Pharmacology and Therapeutics in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Additional Research. The editors have built Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Additional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Pharmaceuticals by Disease, Disorder, or Organ System. The editors have built Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Pharmaceuticals by Disease, Disorder, or Organ System in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Pharmaceuticals by Disease, Disorder, or Organ System: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Drs. Robert Kotloff and Francis McCormack have assembled an expert team of authors on the topic of Rare and Orphan Lung Diseases. Articles include: Lymphangioleiomyomatosis, Pulmonary Lymphangiomatosis, Langerhans Cell Histiocytosis and other Histiocytic Diseases of the Lung, Pulmonary Alveolar Proteinosis, Pulmonary Alveolar Microlithiasis, Primary Ciliary Dyskinesia, Birt-Hogg-Dube Syndrome, Hermansky-Pudlak Syndrome, Hereditary Hemorrhagic Telangiectasia, Non-CF Bronchiectasis, Eosinophilic Lung Diseases, Benign Metastasizing Leiomyomata, and more!

This issue of Radiologic Clinics of North America focuses on Imaging of Selected Multi-System Disorders. Articles will include: von Hippel-Lindau syndrome: Review of Genetics and Imaging; Cross-sectional Imaging Review of Tuberous Sclerosis; Multiple Endocrine Neoplasia Syndromes: A Comprehensive Imaging Review; Imaging Manifestations of Thoracic Tuberculosis; Imaging Spectrum of Extra-Thoracic Tuberculosis; MDCT and MRI Findings of Mycotic Infections; Imaging of Sarcoidosis: A Contemporary Review; Imaging of Inflammatory Myofibroblastic Tumor; Recent Advances in Imaging of IgG4-related Disease; Systemic Vasculopathy Syndromes: Overview of Imaging & Management; Taxonomy and Imaging Manifestations of Systemic Amyloidosis; State of the Art Imaging & Staging of Multiple Myeloma & Plasmacytoma; Solitary Fibrous Tumor: 2016 Imaging Update; and more!

Issues in Birth Defects and Congenital and Genetic Diseases and Disorders: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Birth Defects in a compact format. The editors have built Issues in Birth Defects and Congenital and Genetic Diseases and Disorders: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Birth Defects in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Birth Defects and Congenital and Genetic Diseases and Disorders: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.

This issue of Immunology and Allergy Clinics of North America, Guest Edited by Amy D. Klion, MD and Princess U. Ogbogu, MD, is devoted to Eosinophil-Associated Disorders. Drs. Klion and Ogbogu have assembled a group of expert authors to review the following topics: Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia; Spectrum of Eosinophilic End Organ Manifestations; Eosinophilia in GI disorders; Eosinophilia in Hematologic Disorders; Eosinophilia in Rheumatologic/Vascular Disorders; Eosinophilia in Pulmonary Disorders; Eosinophilia in Infectious Diseases; Eosinophilia associated with Immune Deficiency and Immune Dysregulation; Eosinophilia in Dermatologic disorders; Management of Hypereosinophilic Syndromes; and Novel Therapies for Eosinophilic Disorders.

Vasculitis is a term for a group of rare diseases that have in common inflammation of blood vessels and there are many types of vasculitis, and they may vary greatly in symptoms, severity and duration. Vasculitis can range from mild to life-threatening and early detection and treatment of severe vasculitis can prevent permanent damage.